What Is Stronger Than Tramadol: Opioids Ranked

Tramadol sits near the bottom of the opioid potency ladder. Most prescription opioids commonly used for moderate-to-severe pain, including hydrocodone, oxycodone, morphine, and fentanyl, are stronger. Where tramadol gets interesting is in why it is so weak compared to its relatives: it works through a split mechanism that only partially relies on the same receptor other opioids target, and its pain-relieving power depends heavily on a liver enzyme that varies wildly from person to person. Ranking opioids by strength sounds straightforward, but the picture gets complicated once you account for how each drug actually behaves in the body.

Why Tramadol Is Relatively Weak

Tramadol is classified as a mixed-mechanism opioid. It binds to mu-opioid receptors, the same target morphine and fentanyl hit, but it also blocks the reuptake of serotonin and norepinephrine, two brain chemicals involved in pain signaling and mood. That dual action is what sets tramadol apart from conventional opioids and is also what limits its raw analgesic punch.

The opioid component of tramadol is fairly mild on its own. Much of its mu-receptor activity actually comes not from tramadol itself but from a metabolite called O-desmethyltramadol, which the liver produces using an enzyme called CYP2D6. When that enzyme is blocked or genetically underactive, tramadol’s opioid effect drops substantially. One pharmacokinetic modeling study found that inhibiting CYP2D6 cut exposure to the active metabolite by about half, which translates to meaningfully less pain relief.

Opioids at Roughly the Same Level

Codeine is the opioid most often compared to tramadol, and the two land in a similar range. In a meta-analysis of over 3,400 postoperative patients, tramadol 150 mg performed comparably to combination analgesics containing codeine 60 mg with aspirin or acetaminophen.¹ A separate dental-extraction trial found that tramadol had similar pain-relieving properties to codeine but with fewer side effects like constipation, euphoria, and slowed breathing.²

Codeine shares tramadol’s reliance on CYP2D6 for activation, which means both drugs underperform in the same subset of the population. The key practical difference is that tramadol’s monoamine reuptake activity gives it a slightly broader mechanism, which can be helpful for certain pain types but also introduces unique risks covered later in this article.

The Step Up From Tramadol

Hydrocodone

Hydrocodone, typically combined with acetaminophen, is one of the most widely prescribed opioids and sits a clear step above tramadol in potency. A randomized trial in emergency department patients with acute musculoskeletal pain found that hydrocodone-acetaminophen produced significantly lower pain scores than tramadol starting at 30 minutes and continuing through three hours.³ Both groups started at the same baseline pain level, so the difference was genuinely about drug strength, not patient selection. In equianalgesic terms, hydrocodone is roughly comparable to morphine milligram-for-milligram when taken orally.

Tapentadol

Tapentadol is an interesting case because it shares tramadol’s dual mechanism, acting as both a mu-opioid agonist and a monoamine reuptake inhibitor, but it is substantially more potent. A comparative review concluded that tapentadol is roughly two to three times stronger than tramadol and two to three times weaker than morphine.⁴ A head-to-head study in patients after cardiac surgery also found tapentadol to be a better analgesic than tramadol, with less post-operative nausea and vomiting.⁵

Unlike tramadol, tapentadol does not require CYP2D6 activation to work, which means its effect is more consistent across individuals. For people who metabolize tramadol poorly, tapentadol can be a more reliable option in the same mechanistic family.

Morphine and the Drugs Benchmarked Against It

Morphine is the reference standard for opioid potency. Virtually all equianalgesic dose charts use morphine as the baseline, converting every other opioid into “morphine milligram equivalents” so that prescribers can compare drugs on equal footing.⁶ The NIH recently developed a standardized calculator covering 29 opioids, drawing on evidence from studies published over more than seven decades, to improve consistency in how researchers and clinicians make these conversions.⁷

Morphine is several times more potent than tramadol. Exact ratios vary depending on the source and the route of administration, but oral tramadol typically requires roughly ten times the milligram dose of oral morphine to achieve the same level of pain relief. That gap explains why tramadol is classified as a Step 2 analgesic in pain management frameworks while morphine is reserved for Step 3, when moderate agents are no longer enough.

Oxycodone

Oxycodone falls in the same general tier as morphine, usually estimated at roughly 1.5 times oral morphine’s potency. It is one of the most commonly prescribed strong opioids and considerably more powerful than tramadol. In older adults, oxycodone carries meaningful safety differences compared to weaker opioids: a large comparative safety study found that oxycodone users had an elevated risk of death within just the first 30 days of treatment, while tramadol users actually had a significantly reduced risk of fractures during that same window.⁸ That safety gap is part of why tramadol, despite its weakness, remains a first-line choice for many patients.

The High-Potency Tier

Hydromorphone

Hydromorphone is often described as a stronger cousin of morphine, typically estimated at about five times morphine’s potency when given intravenously. It is frequently used in hospitals for severe pain when morphine alone is insufficient or poorly tolerated. Compared to tramadol, the potency gap is enormous; a dose of hydromorphone measured in single-digit milligrams can match what would require hundreds of milligrams of tramadol.

Oxymorphone

Oxymorphone sits above hydromorphone. A pilot study measuring abuse-related subjective effects found that intravenous oxymorphone was roughly 2.3 to 2.8 times more potent than hydromorphone and about 12.5 to 14 times more potent than oxycodone.⁹ Those are striking numbers, and they place oxymorphone many dozens of times stronger than tramadol on a milligram-for-milligram basis.

Fentanyl

Fentanyl is commonly quoted as 50 to 100 times more potent than morphine, making it several hundred times stronger than tramadol. It is used medically in patches, lozenges, and intravenous formulations for severe pain, particularly in cancer patients or during surgery. Its potency allows effective pain control in microgram-level doses, something unthinkable with tramadol. The speed at which fentanyl crosses into the brain contributes to both its clinical usefulness and its danger in non-medical contexts.

Synthetics Beyond Fentanyl

The upper reaches of the opioid potency spectrum involve drugs that are rarely or never used in standard medicine. Carfentanil, developed as a large-animal tranquilizer, is estimated to be roughly 100 times more potent than fentanyl. Nitazenes, a class of synthetic opioids increasingly found in illicit drug supplies, are similarly potent.

What makes these drugs particularly dangerous goes beyond raw strength. Research on receptor behavior found that while morphine, fentanyl, and the related compound alfentanil detach from the mu-opioid receptor quickly, carfentanil, ohmefentanyl, and nitazene-class compounds like isotonitazene and etonitazene cling to the receptor much longer.¹⁰ Slow dissociation means naloxone, the standard overdose-reversal drug, has a harder time dislodging these compounds. An overdose involving carfentanil or nitazenes may require repeated or higher doses of naloxone to reverse, and the window for intervention is narrower.

When “Stronger” Does Not Mean What You Think

Two opioids break the simple “more potent = more dangerous” logic in different ways: buprenorphine and methadone.

Buprenorphine binds to the mu-opioid receptor with extremely high affinity, meaning it grips the receptor tightly and can displace other opioids already sitting there. But it is a partial agonist, so even at high doses, it only partially activates the receptor. This creates a ceiling effect on respiratory depression, which is the mechanism by which opioid overdoses kill people.¹¹ In terms of binding strength, buprenorphine outmuscles morphine and even fentanyl. But in terms of maximum pain relief it can deliver, it hits a ceiling well below full agonists. That combination, strong binding with limited activation, is exactly what makes it useful for treating opioid use disorder: it satisfies the receptor enough to prevent withdrawal without producing the full high or the full respiratory risk of drugs like heroin or fentanyl. A review of agonist-antagonist mechanisms confirmed that this ceiling reflects limited intrinsic efficacy at the receptor, not a shift to blocking activity at higher doses.¹²

Methadone is a full agonist but complicates potency rankings in its own way. It acts on the mu-opioid receptor like morphine, but it also blocks NMDA receptors, a completely separate target involved in nerve-based pain and the development of opioid tolerance.¹³ That dual action means methadone can sometimes control pain that other opioids cannot, even at what looks like a modest equivalent dose. Its potency relative to morphine also shifts depending on the dose a patient is already taking: at lower doses, methadone is roughly equivalent to morphine, but at higher morphine-equivalent doses, methadone becomes proportionally stronger. It also has a very long and unpredictable half-life, which makes dose adjustments risky. For these reasons, methadone is effective but difficult to rank on a simple potency chart.

Your Genetics Change Tramadol’s Position on the Ladder

Because tramadol depends on CYP2D6 to produce its active metabolite, your genetic profile for that enzyme meaningfully shifts how strong tramadol actually is for you. People fall into several metabolizer categories. A study of postoperative patients found that poor metabolizers had a non-response rate to tramadol of nearly 47%, compared to about 22% among normal metabolizers.¹⁴ Poor metabolizers also needed higher loading doses and were roughly twice as likely to require rescue medication.

Intermediate metabolizers also show reduced tramadol effectiveness. A population pharmacokinetic study found that CYP2D6 intermediate metabolizers had about 20% lower clearance of tramadol’s active metabolite after a single dose, with the gap widening to about 40% higher drug exposure at steady state.¹⁵ That sounds like it should mean more pain relief, but the metabolite balance shifts in unpredictable ways; what matters is the ratio between the parent drug and the active metabolite, not just the total amount of either one in the blood.

On the other end of the spectrum, ultra-rapid metabolizers convert tramadol to its active form faster than intended, which can produce unexpectedly strong opioid effects and increase the risk of side effects. For these individuals, tramadol effectively punches above its weight class, sometimes significantly. Roughly 5 to 10% of people of European descent are ultra-rapid metabolizers for CYP2D6, with the proportion varying substantially across ethnic groups.

This genetic variability is part of what makes tramadol’s place on any potency ranking inherently fuzzy. For a poor metabolizer, tramadol barely functions as an opioid at all. For an ultra-rapid metabolizer, it may approach the territory of a stronger drug. Most other opioids do not have this degree of genetic dependence.

Tramadol’s Unusual Risk Profile

Tramadol’s monoamine reuptake-blocking activity, the same feature that makes it a weaker opioid, gives it a side-effect profile unlike stronger opioids. The two standout risks are seizures and serotonin syndrome. Both can occur with tramadol alone but are more likely during overdose or when tramadol is taken alongside antidepressants, particularly SSRIs and SNRIs.¹⁶

Serotonin syndrome is a potentially life-threatening condition that occurs when serotonin levels in the brain spike too high. Symptoms include agitation, rapid heart rate, high body temperature, muscle rigidity, and in severe cases, organ failure. This risk is essentially absent with pure opioid agonists like morphine or oxycodone, because they do not touch the serotonin system. Tramadol’s lower respiratory depression risk relative to stronger opioids is often cited as a safety advantage, but the seizure and serotonin risks represent a trade-off that is not always well understood by patients or even prescribers.¹⁷ A study of tramadol-intoxicated patients confirmed that high plasma concentrations of the drug play a key role in triggering both seizures and serotonin toxicity.¹⁸

The practical takeaway is that “weaker” does not automatically mean “safer” in every scenario. A patient on an SSRI antidepressant may actually face a more serious interaction risk from tramadol than from a conventional opioid that is technically more potent.

Opioid Safety in Older Adults

The potency ranking takes on a different flavor in older adults, where the safety gap between opioids becomes especially stark. In a large comparative study of adults averaging 79 years old with non-cancer pain, tramadol users had a dramatically lower fracture risk during the first 30 days of treatment compared to users of other opioids. Codeine and oxycodone users, by contrast, showed elevated mortality risk within the first month of treatment.⁸

Fracture risk matters in this population because opioids cause sedation and dizziness, and falls are a leading cause of hospitalization and death in older adults. Tramadol’s milder opioid activity may explain why it performed better on this measure. The finding does not mean tramadol is harmless in older adults; it still carries the seizure risk described above, and its unpredictable metabolism can be compounded by the polypharmacy common in elderly patients. But for mild-to-moderate pain in this group, tramadol’s relatively low potency is genuinely protective in ways that matter more than the potency ranking alone would suggest.

A Rough Ranking, Weakest to Strongest

For a general sense of how prescription opioids stack up relative to tramadol, here is an approximate ordering by oral equianalgesic potency. These are rough clinical estimates and vary by source, route, and individual patient factors:

Codeine: Similar to tramadol, or slightly weaker depending on the study. Both require CYP2D6 activation.
Tramadol: The baseline for this comparison. Roughly one-tenth the potency of oral morphine.
Tapentadol: About two to three times stronger than tramadol.
Hydrocodone: Roughly equivalent to oral morphine.
Morphine: The reference standard. About ten times stronger than tramadol.
Oxycodone: About 1.5 times oral morphine.
Methadone: Variable, but at high doses can exceed morphine’s potency by a wide margin.
Hydromorphone: Roughly five times morphine intravenously.
Oxymorphone: Multiple times stronger than hydromorphone.
Fentanyl: 50 to 100 times morphine, hundreds of times stronger than tramadol.
Carfentanil and nitazenes: Thousands of times stronger than tramadol. Not used in standard human medicine.

Buprenorphine is deliberately left off this list because its partial-agonist ceiling means it does not fit neatly into a linear potency ranking. It binds more tightly than most opioids on this list but activates the receptor less, making it simultaneously “stronger” and “weaker” depending on what you are measuring.

Why Potency Charts Have Limits

Equianalgesic charts are clinical tools, not absolute truths. They are built from averages across study populations, and individual responses to any given opioid vary based on genetics, prior opioid exposure, organ function, and the type of pain being treated. The NIH’s recently developed morphine milligram equivalent calculator drew on evidence from 24 studies spanning 75 years, and even with that depth of data, the conversion factors are best understood as starting points for clinical judgment rather than precise equivalences.⁷

The direction of the ranking is reliable: fentanyl is always much stronger than morphine, and morphine is always much stronger than tramadol. But the exact multiplier for any given patient depends on factors no chart can capture. A clinician switching a patient from one opioid to another typically starts at a lower-than-calculated dose and titrates up, specifically because the charts are approximations. For tramadol in particular, CYP2D6 status can shift its effective potency by enough to matter clinically, a wrinkle that does not apply to most drugs higher on the list.¹⁴

1
PubMed. Single-patient data meta-analysis of 3453 postoperative patients: oral tramadol versus placebo, codeine and combination analgesics
2
PubMed. Tramadol hydrochloride: analgesic efficacy compared with codeine, aspirin with codeine, and placebo after dental extraction
3
PubMed. Tramadol versus hydrocodone-acetaminophen in acute musculoskeletal pain: a randomized, double-blind clinical trial
4
PubMed Central. Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients
5
PubMed Central. Comparison of tapentadol with tramadol for analgesia after cardiac surgery
6
PubMed Central. Morphine Equianalgesic Dose Chart in the Emergency Department
7
Ovid / Wolters Kluwer Health (Pain). Standardizing research methods for opioid dose comparison: the NIH HEAL morphine milligram equivalent calculator
8
JAMA Internal Medicine. The Comparative Safety of Opioids for Nonmalignant Pain in Older Adults
9
Psychopharmacology. Relative potency of intravenous oxymorphone compared to other µ opioid agonists in humans — pilot study outcomes
10
bioRxiv. Potency, dissociation kinetics and reversibility of fentanyls and nitazenes by naloxone at the μ opioid receptor
11
PubMed Central. The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal
12
PubMed Central. Opioid receptor agonist-antagonists in pain management: receptor specific mechanisms, dose response relationships, and clinical combination strategies
13
PubMed Central. Methadone for Chronic Pain: A Review of Pharmacology, Efficacy, and Safety Concerns
14
PubMed. Impact of CYP2D6 genotype on postoperative tramadol analgesia
15
PubMed Central. Role of Pharmacogenetics on Tramadol Pharmacokinetics: A Population Pharmacokinetic Model
16
PubMed Central. Tramadol: seizures, serotonin syndrome, and coadministered antidepressants
17
The American Journal of Medicine. Clinical management of tramadol-related seizures and serotonin syndrome
18
PubMed. Clinical and Laboratory Factors Related to Seizure and Serotonin Toxicity in Tramadol Intoxication: An Egyptian Study